| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/02/2001 | US6297022 Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 |
| 10/02/2001 | US6297004 Retroviral particles that infect eukaryotic cells; for somatic gene therapy; for use as diagnostic tool in viral detection; viricides |
| 10/02/2001 | US6297003 Methods for the detection of a novel hepatitis C virus (HCV) terminal 3′ noncoding region |
| 10/02/2001 | US6296855 17-KDA Brucella abortus antigen, recombinant polypeptides, nucleic acids coding for the same and use thereof in diagnostic and prophylactic methods and kits |
| 10/02/2001 | US6296854 Live attenuated Venezuelan Equire encephalitis vaccine |
| 10/02/2001 | US6296853 For therapy of animal having a papilloma viral infection |
| 10/02/2001 | US6296852 For protecting poultry from disease; used to generate immune response in commercial poultry |
| 10/02/2001 | US6296851 For screening antibiotics |
| 10/02/2001 | US6296850 Apoptosis-related compounds and their use |
| 10/02/2001 | US6296849 Methods and compositions including a 13kDa B. burgdorferi protein |
| 10/02/2001 | US6296847 Composition for treating benign prostatic hypertrophy |
| 10/02/2001 | US6296846 Induced tolerance to xenografts |
| 10/02/2001 | US6296832 Molecular medicine and drug delivery; in vivo panning for identifying molecule that homes to a specific organ |
| 10/02/2001 | US6296807 Kits for the detection of human immunodeficiency virus type 2 (HIV-2) antigens |
| 10/02/2001 | CA2020668C Fused or hybrid protein comprising viral antigen and lymphokine |
| 09/30/2001 | CA2310365A1 Passive and active protection against mycobacterial infections |
| 09/27/2001 | WO2001071358A1 Method of screening for inhibitors of osteopontin |
| 09/27/2001 | WO2001071352A2 Compositions associated with complex formation |
| 09/27/2001 | WO2001071005A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | WO2001070992A1 Proteins and polypeptides from haemophilus influenza involved in paracytosis, nucleotide sequences encoding them and uses thereof |
| 09/27/2001 | WO2001070991A1 Vaccine against mycobacterium infection based on epitopes of ag85 complex |
| 09/27/2001 | WO2001070984A2 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 09/27/2001 | WO2001070978A2 Polypeptides and nucleic acids encoding same |
| 09/27/2001 | WO2001070975A1 Novel melanin concentrating hormone receptor |
| 09/27/2001 | WO2001070964A1 A novel polypeptide, a human glucose transport like protein 18 and the polynucleotide encoding the polypeptide |
| 09/27/2001 | WO2001070953A2 Identification of modulators of the inteferon gamma signaling pathway and their use in restenosis treatment |
| 09/27/2001 | WO2001070941A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | WO2001070932A2 Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife |
| 09/27/2001 | WO2001070808A2 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 09/27/2001 | WO2001070799A1 Novel protein having hemolytic activity and gene encoding the protein |
| 09/27/2001 | WO2001070776A2 Nimr compositions and their methods of use |
| 09/27/2001 | WO2001070775A2 Wnt-1 related polypeptides, and nucleic acids encoding the same |
| 09/27/2001 | WO2001070774A2 Human t cell response to mhc-binding motif clusters |
| 09/27/2001 | WO2001070772A2 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid |
| 09/27/2001 | WO2001070771A2 Acute neuronal induced calcium binding protein type 1 ligand |
| 09/27/2001 | WO2001070767A2 Therapeutic anti-melanoma compounds |
| 09/27/2001 | WO2001070766A2 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | WO2001070764A2 Epitopes of mycobacterium tuberculosis secreted antigens and uses thereof |
| 09/27/2001 | WO2001070663A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | WO2001070268A1 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
| 09/27/2001 | WO2001070267A1 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 09/27/2001 | WO2001070266A2 Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| 09/27/2001 | WO2001070265A2 Lipopeptide adjuvants |
| 09/27/2001 | WO2001070264A1 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant |
| 09/27/2001 | WO2001070263A1 Composition and method for the prevention and/or the treatment of allergy |
| 09/27/2001 | WO2001070262A2 A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
| 09/27/2001 | WO2001070260A1 Cd18-binding antibodies inhibit stenosis-related disorders |
| 09/27/2001 | WO2001070257A1 Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity |
| 09/27/2001 | WO2001070255A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 09/27/2001 | WO2001070253A1 Use of mia in immunotherapy |
| 09/27/2001 | WO2001070252A1 Novel borrelia burgdorferi polypeptides and uses thereof |
| 09/27/2001 | WO2001070247A2 Salmonella vaccine materials and methods |
| 09/27/2001 | WO2001070245A1 Immune mediators and related methods |
| 09/27/2001 | WO2001070244A1 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses |
| 09/27/2001 | WO2001070200A1 Pharmaceutical composition for administration to mucosal surfaces |
| 09/27/2001 | WO2001070174A2 Vegf-modulated genes and methods employing them |
| 09/27/2001 | WO2001070032A1 Recombinant parainfluenza virus expression systems and vaccines |
| 09/27/2001 | WO2001021802B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/27/2001 | WO2001021207A3 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 09/27/2001 | WO2001020013A3 Viral replicons and viruses dependent on inducing agents |
| 09/27/2001 | WO2001019992A3 FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES |
| 09/27/2001 | WO2001018546A3 Screening for inhibitors of 'paired helical filaments' |
| 09/27/2001 | WO2001017558A3 Novel uses of mammalian ccr6 receptors and related reagents |
| 09/27/2001 | WO2001017551A3 Combined vaccine compositions |
| 09/27/2001 | WO2001016170A3 Card proteins involved in cell death regulation |
| 09/27/2001 | WO2001000665A3 Inhibitors of memapsin 2 and use thereof |
| 09/27/2001 | WO2000057837A8 Compositions and methods for effecting the levels of cholesterol |
| 09/27/2001 | US20010025026 Chimeric proteins for use in transport of a selected substance into cells |
| 09/27/2001 | US20010024824 Stem cells and their use in transplantation |
| 09/27/2001 | US20010024817 Viral nucleotide sequences |
| 09/27/2001 | US20010024651 Method for inducing a systemic immune response to an antigen |
| 09/27/2001 | US20010024650 Artery - and vein-specific proteins and uses therefor |
| 09/27/2001 | US20010024649 Topical treatment comprises an ester or amide lipophilic molecule capable of traversing the statum corneum and inducing immature dendritic cells to migrat to the draining lymphoid organ |
| 09/27/2001 | US20010024648 Four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effeftive immunosuppressants for the treatment of autoimmune diseases and prevent organ trasplant rejection |
| 09/27/2001 | US20010024647 Single chain variable region immunoglobulin (ScFv) fragment antibody that binds selectively to the active conformation of human von Willebrand Factor (vWF) and the antibody inhibits the binding of vWF to platelets |
| 09/27/2001 | US20010023664 Chicken anaemia viruses of low pathogenicity |
| 09/27/2001 | DE10012370A1 Use of oil-in-water emulsion as vaccine adjuvant, particularly for influenza and pneumococcal vaccines, administered at different site from the vaccine |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2404327A1 Lipopeptide adjuvants |
| 09/27/2001 | CA2404216A1 Novel polypeptides, and nucleic acids encoding the same |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403809A1 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 09/27/2001 | CA2403804A1 Vegf-modulated genes and methods employing them |
| 09/27/2001 | CA2403803A1 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid |
| 09/27/2001 | CA2403718A1 A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
| 09/27/2001 | CA2403684A1 Therapeutic anti-melanoma compounds |
| 09/27/2001 | CA2403681A1 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | CA2403553A1 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | CA2403444A1 Restenosis treatment |
| 09/27/2001 | CA2403436A1 Acute neuronal induced calcium binding protein type 1 ligand |
| 09/27/2001 | CA2403432A1 Immune mediators and related methods |
| 09/27/2001 | CA2403359A1 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 09/27/2001 | CA2402727A1 Novel borrelia burgdorferi polypeptides and uses thereof |
| 09/27/2001 | CA2402636A1 Composition and method for the prevention and/or the treatment of allergy |
| 09/27/2001 | CA2402596A1 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 09/27/2001 | CA2402285A1 Nimr compositions and their methods of use |
| 09/27/2001 | CA2402252A1 Salmonella vaccine materials and methods |
| 09/27/2001 | CA2399695A1 Pharmaceutical composition for administration to mucosal surfaces |
| 09/27/2001 | CA2399028A1 Use of mia in immunotherapy |
| 09/27/2001 | CA2374073A1 Novel polypeptides and nucleic acids encoding same |